display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - triple negative
mBC - TNBC - L1 - all populationmBC-Triple negative (TNBC) - 2nd Line (L2)mBC - TNBC - L2 - all populationes-BC - TNBC - NA - all population
poly ADP-ribose polymerase (PARP) inhibitor
olaparib OlympiAD OlympiA ...
talazoparib EMBRACA
veliparib plus paclitaxel plus carboplatin BrighTNess ... BrighTNess ...

Study type: